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Abstract
Regulatory T cells (Tregs), a subset of CD4+ T cells plays a pivotal role in regulating the immune system. An increase in Treg
numbers enables cancer progression by dampening the immune system and allowing tumor cells to evade immune
detection and destruction. An increase in Treg numbers and expression of inhibitory cytokines including TGF-b and IL-10 are
mechanisms by which Tregs exert their immune suppressive function. However, the presence of Tregs and inhibitory
cytokines in oral cancer patients is still unclear. In this study, the presence of circulating Tregs in 39 oral cancer patients and
24 healthy donors was examined by studying the presence of the CD4+CD25hiCD127low cell population in their peripheral
blood mononuclear cells using flow cytometry. Serum levels of TGF-b and IL-10 were measured by ELISA. T cell subsets of
OSCC patients were found to differ significantly from healthy donors where a decrease in CD8+ cytotoxic T cells and an
increase in Tregs (CD4+CD25hiCD127low) were observed. Further, the ratio of CD8+ T cells/Tregs was also decreased in
patients compared to healthy donors. The presence of Tregs was accompanied by a decrease in IL-10 but not TGF-b
secretion in OSCC patients when compared to donors; in addition, the analysis also revealed that an increased presence of
Tregs was accompanied by better patient survival. Amongst OSCC patients, smokers had significantly higher levels of TGF-b.
It is apparent that the immune system is compromised in OSCC patients and the characterization of the Treg subpopulation
could form a basis for improving our understanding of the perturbations in the immune system that occur during OSCC
tumorigenesis.
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Introduction
The inability of the immune system to eradicate established
tumors is a well-recognized hallmark of cancer [1,2]. Tumors can
employ numerous mechanisms to suppress host immunity and in
particular, many studies have focused on the role of regulatory T
cells (Tregs) in helping tumors evade immune surveillance [3–6].
Whilst Tregs are important regulators of immune-mediated
inflammation, they have been demonstrated to be equally critical
as mediators of active immune evasion; the depletion of these cells
can improve endogenous anti-tumor immunity and efficacy of
immunotherapy [7,8]. This realization has resulted in the
development of strategies to target the immunosuppressive arm
of the immune system [9,10].
Treg-mediated suppression can occur through several mecha-
nisms, either by cell-cell contact or by secretion of cytokines (TGF-
b and IL-10) [11]. The involvement of Tregs in tumor progression
in patients with lung, head and neck, prostate, and breast cancers
has been demonstrated, where there are increased levels of these
cells in the peripheral blood [12–15]. Further, levels of IL-10
which mediates immune suppression by down-regulating MHC
class I expression or by inhibiting T cell activation were shown to
be increased in many types of cancers including melanoma, head
and neck, pancreatic, gastric, lung, and breast [16–23]. TGF-b is a
potent suppressor of the immune system and it inhibits the
secretion of immunoglobulin (Ig) M, IgG1, IgG2a and IgG3 [24].
Neutralizing antibodies to TGF-b have been shown to reverse
Treg-mediated suppression in inflammatory bowel disease (IBD) in
mice and thyroiditis in rats [25,26]. In the main, the presence of
Tregs has been associated with poor disease outcome, however,
contradictory reports exists [12,13,15,27–34]. The discrepancies
happen in part because of the multiple markers that are used to
identify the Treg population. Markers delineating these cells
include CD25, cytotoxic T lymphocyte-associated antigen 4
(CTLA-4), glucocorticoid-induced tumor necrosis factor receptor
family-related gene (GITR), lymphocyte activation gene-3 (LAG-
3), CD127 and forkhead / winged-helix transcription factor box
P3 (FOXP3) [26,35–39]. As many of these markers are also
markers of T cell activation [40], CD4+CD25+FOXP3+ and
CD4+CD25+CD127low remain the most well accepted markers for
the identification of Tregs, as cells with these phenotypes are
immunosuppressive [41–43].
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Head and neck cancers pose a significant global burden [44,45]
and oral cancer, a subset of head and neck cancers occurs in about
400,000 individuals world-wide, and contribute to more than
222,000 deaths annually [44,46]. Moreover 50% of oral cancer
patients suffer from disease recurrence or secondary tumors [47–
49]. As we begin to identify key genetic drivers through the
compilation of gene expression, chromosomal copy number and
sequencing data for many types of solid tumors [50,51], the
development of novel treatments (especially immunotherapy) to
target some of the mutations arising from these genetic events is
currently possible [52]. However, the presence of immune
suppression in patients could still hinder the success of these novel
treatment modalities. In this study, the immunological status of
oral cancer patients was characterized by looking at their
lymphocyte subsets, and the levels of IL-10 and TGF-b with the
hypothesis that OSCC patients would have a compromised
immune system with an increased presence of Tregs and levels
of IL-10 and TGF-b. A significant increase in CD4+CD25hiC-
D127low sub-population of Tregs in OSCC patients and a novel
subpopulation of CD4+CD25hi that completely lacked of CD127
expression was found in OSCC patients. Further, the presence of
regulatory T cells was accompanied by a decrease in IL-10 but not
TGF-b secretion. Our results show that the level of Tregs differs
between OSCC patients and normal individuals suggesting that
these cells may play a major role in oral carcinogenesis.
Materials and Methods
Peripheral Blood Mononuclear Cell (PBMC) isolation
Thirty-nine OSCC patients (no prior treatment) and 24 healthy
donors were included in this study. Healthy donors were recruited
from relatives or friends who accompanied the patient and at
blood donation drives. All individuals were briefed regarding the
project prior to obtaining written consent; in the event of an
individual who was unable to provide written consent due to the
inability to write, written consent was either obtained in the form
of a thumb print or from the next of kin. All consent documents
were filed and kept for future reference in the Oral Cancer
Research & Coordinating Centre (OCRCC), Faculty of Dentistry,
University of Malaya. All relevant documents and procedures
were approved by the institutional review board of the Faculty of
Dentistry Medical Ethics Committee, University Malaya (Medical
ethics number: DF OS0910/0049(L). Eight to thirty milliliters of
peripheral blood was collected from each of these individuals in
BD Vacutainer CPT tubes (Becton Dickinson, NJ, USA).
Peripheral blood mononuclear cells (PBMC) were isolated from
the peripheral blood, washed in Hanks balanced salt solution
(HBSS; Gibco, Life Technologies, California, USA) and re-
suspended in complete culture medium [Roswell Park Memorial
Institute Medium (RPMI; Gibco, Life Technologies, California,
USA) supplemented with 5% heat-inactivated human AB serum
(Gemini Bio-Product, California, USA) and 16 penicillin/
Figure 1. Gating used for the identification of circulating T cell subsets in human. Multiparameter flow cytometry analyses of CD4+CD25hi,
CD4+CD25hiCD127low and CD4+CD25hiCD127nil regulatory T cells subsets. Gates were set on (a) T lymphocytes (based on forward and side scatter), (b)
CD4+ T cells, (c) CD4+CD25hi and (d) CD4+CD25hiCD127low and CD4+CD25hiCD127nil.
doi:10.1371/journal.pone.0103975.g001
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streptomycin (Gibco, Life Technologies, California, USA)].
PBMC (16106)were used for the assays as described below.
Identifying circulating T cell subsets
The presence of Tregs was determined in 35 OSCC patients
and 14 healthy donors by measuring the following markers: CD4
(BD Biosciences-Pharmingen, California, USA), CD25 (e-Biosci-
ence, CA, USA) and CD127 (BD Biosciences-Pharmingen,
California, USA). Briefly, 56105 fresh PBMCs were incubated
with specific antibodies conjugated with fluorochrome (0.42 mg/
ml of CD25-APC, 0.33 mg/ml of CD4-FITC and 0.33 mg/ml of
CD127-PE) for 30 minutes at 4uC. The cells were then washed
using phosphate buffered saline (PBS), resuspended in Pharmingen
Stain Buffer (PSB) and analyzed using a flow cytometer
Table 1. Patients’ demographic data.
Variables OSCC
Age (year) Mean ± SD: 58±13 n %
Gender Male 8 21
Female 31 79
Ethnic Malay 3 8
Chinese 4 10
Indian 31 79
Others* 1 3
Habits Ever Smoker 6 15
Ever Drinker 5 13
Ever Chewer 23 59
No habit 10 26
Stage Early (stage I & II) 13 33
Late (stage III & IV) 23 59
Data not available 3 8
Disease sites Cheek 16 41
Tongue 10 26
Gingiva 5 13
Others** 7 18
Data not available 1 2
*Others: Indigenous population.
** Others: Lip, palate, floor of mouth.
doi:10.1371/journal.pone.0103975.t001
Figure 2. Reduction of cytotoxic T cells (CD8+) is a characteristic of OSCC patients. (a) Percentage of cytotoxic T lymphocytes (CD8+) in
both OSCC patients and healthy donors; (b) Percentage of helper T cells (CD4+) in both OSCC patients and healthy donors. Each symbol represents an
individual and the narrow bar represents the mean percentage of the specific cell population.
doi:10.1371/journal.pone.0103975.g002
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(FACSCalibur, BD Biosciences, California, USA). The presence of
Tregs was then analyzed using FACSDiva analysis software (BD
Biosciences, California, USA). Briefly, 50,000–100,000 cells were
collected and lymphocyte population was gated based on cell size
(Figure 1a) and the presence of helper T cells (CD4+),
CD4+CD25hi and CD4+CD25hiCD127low cells were further
determined from the CD4+ cell population (Figure 1b, c, d). In
addition, the presence of CD4+CD25hiCD127nil cells were also
identified (Figure 1d). Similarly, CD4+ and CD8+ T cell subsets
were detected with TCR-APC (Miltenyi Biotec, Surrey, UK),
CD4-FITC (BD Biosciences-Pharmingen, California, USA) and
CD8-PE (Invitrogen, NY, USA) antibodies and stained as
described above in 35 OSCC patients, 9 healthy donors and 27
OSCC patients and 9 healthy donors respectively.
Measurement of IL-10 and TGF-b by Enzyme-linked
Immunosorbent Assay (ELISA)
The levels of two cytokines (IL-10 and TGF-b) which are known
to be involved in the immunosuppressive function of Tregs were
analyzed in 30 OSCC patients and 16 healthy donors using
ELISA, according to the manufacturer’s protocol (Invitrogen, New
York, USA). Prior to analyzing TGF-b levels, 100 ml of serum was
activated by adding 4 ml of 1N HCl and incubated at room
temperature for 15 minutes and neutralized using 3 ml 1N NaOH.
The activated serum was then diluted 46 with assay buffer and
dispensed into 96 well plates which were pre-coated with TGF-b
antibody, this was followed by the addition of the detection
antibody and streptavidin-HRP conjugate. The specific binding
was visualized after adding the substrate solution. A standard
curve (log-log curve fit) was generated using respective recombi-
nant human cytokine and the absolute concentration of cytokine
in the serum was determined from this curve. Detection of IL-10
levels was performed as described above without the serum
activation procedure.
Statistical analysis
All statistical analyses were performed using the statistical
software package SPSS 16 (SPSS Inc., Chicago, IL, USA) and
GraphPad Prism software (GraphPad Inc., CA, USA). Indepen-
dent t-test was used to compare the differences of immune cells/
cytokines levels in patients and healthy donors. The correlation
between immune cells subsets and cytokines levels with clinico-
Figure 3. CD4+CD25hiCD127low regulatory T cells were up-regulated in OSCC patients. (a) Percentage of CD4+CD25hi T cells amongst
CD4+T cells in OSCC patients and healthy donors; (b) Percentage of CD4+CD25hiCD127low T cells amongst CD4+ T cells in OSCC patients and healthy
donors; (c) Percentage of CD4+CD25hi CD127nil T cells amongst CD4+ T cells in OSCC patients and healthy donors; (d) Ratio of CD8 T cells/
CD4+CD25hiCD127low T cells in OSCC patients and healthy donors; Each symbol represents an individual person and the narrow bar represents the
mean percentage of the specific cell population.
doi:10.1371/journal.pone.0103975.g003
Tregs in Oral Cancer Patients
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e103975
pathological factors was estimated by Fisher’s exact test. Kaplan-
Meier survival analysis was used to correlate survival rates with the
level of CD4+CD25hiCD127low regulatory T cells, the survival
probability differences were compared by log-rank test. A p-value
of ,0.05 was considered to be statistically significant.
Results
Demographic and clinical characteristics of OSCC
patients
The demographic and clinical characteristics of the patients
included in this study are tabulated in Table 1. The mean age of
the OSCC patients was 58613 years (range: 26–76 years). The
ethnic distribution of the patients was representative of the OSCC
patient population in Malaysia where the majority of the patients
were of Indian ethnicity. More than 50% of the patients were
diagnosed with late stage disease (stage III & IV; Table 1). The
mean age of healthy donors was 3268 years (range 24–49 years),
but other demographic information on these individuals were not
available. Survival information was available for 32 of 39 patients,
in which the length of follow up ranged from 2 to 85 months until
May of 2013, with a median survival of 24 months.
Comparison of circulating T cell subsets in OSCC patients
and healthy donors
T lymphocyte subpopulations in OSCC patients and healthy
donors were analyzed using flow cytometry. No difference was
found in the average percentage of T lymphocytes between OSCC
patients and healthy donors (data not shown). However, the
analysis of sub-populations of T lymphocytes demonstrated a
significant reduction in the cytotoxic T cells population (CD8+) in
OSCC patients compared to healthy donors (11.2561.78 vs
19.9862.15; p=0.013; Figure 2a). Further, a decrease in helper T
cells (CD4+) count was also seen in OSCC patients compared to
healthy donors but this difference was not statistically significant
(25.7962.05 vs 31.9262.29; p=0.156; Figure 2b).
The percentage of CD4+CD25hi was significantly elevated in
OSCC patients compared to healthy donors (4.0660.32 vs
2.8460.11; p=0.023; Figure 3a). Notably, the expanded subset
of the CD4+CD25hi cells, the CD4+CD25hi CD127low T cells
(which are indicative of defined regulatory T cells) was promi-
nently higher in OSCC patients compared to healthy donors
(2.5560.19 vs 1.6360.21; p=0.008; Figure 3b). Of note, another
population of cells that totally lacked the expression of CD127 was
detected and designated here as the CD4+CD25hiCD127nil
population; this subpopulation of CD4+CD25hi cells demonstrated
a diverse presence in patients ranging from 0%–23.7% of the
CD4+ T cell population, whilst this diversity was not observed in
healthy donors (0%–0.4% of CD4+ T cells). However, when
comparing the average levels of CD4+CD25hiCD127nil levels, no
significant difference was observed between OSCC patients and
healthy donors (1.3760.74 vs 0.1060.04; p=0.289; Figure 3c).
Given that a significant reduction in CD8+ T cell population and a
prominent increment of the of CD4+CD25hi CD127low regulatory
T cells were observed, the ratio of CD8+ T cell to CD4+CD25hi
CD127low regulatory T cells was further determined; OSCC
patients demonstrated a 3-fold decrease in the ratio as compared
to healthy donors (6.1761.23 vs 17.0764.20; p=0.002).
The presence of TGF-b and IL-10 in the serum of OSCC
patients and healthy donors
We did not find any difference in the level of TGF-b in OSCC
patients compared to healthy donors (837.704674.93 pg/ml vs
810.506133.20 pg/ml; p=0.848; Figure 4a). However, our
results exhibited a significant decrease in the IL-10 level in OSCC
patients as compared to healthy individuals (4.3760.23 pg/ml vs
6.6261.08 pg/ml samples; p= 0.011 Figure 4b).
Correlation of circulating T cell subsets and cytokines
with patient clinico-pathological factors
We analyzed if there were any correlation between of the
percentage of Tregs (CD4+CD25hiCD127low) and the levels of
TGF-b/IL-10 with patient’s clinico-pathological parameters. Our
data showed that OSCC patients who smoke have significantly
higher TGF-b levels compared to non-smokers (p=0.001; Table
2A) but no correlation between IL-10 levels with patients’ clinico-
pathological parameters was observed (Table 2B). Furthermore,
patients who were at early stages of oral cancer had higher levels
CD4+CD25hiCD127low regulatory T cells (p=0.027, Table 3A)
Figure 4. TGF-b and IL-10 levels in OSCC patients and healthy donors. (a) TGF-b concentration of 30 OSCC patients and 16 healthy donors;
(b) IL-10 concentration of 30 OSCC patients and 16 healthy donors. Each symbol represents an individual person and the narrow bar represents the
mean percentage of the specific cell population.
doi:10.1371/journal.pone.0103975.g004
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but this correlation was not seen for the CD8+ T cells/Tregs ratio
(Table 3B). In addition, no association between the levels of Tregs,
IL-10 and TGF-b was found (data not shown).
High levels of CD4+CD25hiCD127low Tregs is associated
with better survival
To evaluate the correlation of the presence of CD4+CD25hiC-
D127low regulatory T cells to patient survival, we used the mean
percentage of CD4+CD25hiCD127low regulatory T cells (2.6%) of
all patients as cut off point and divided patients into those who
have equal or more than 2.6% of CD4+CD25hiCD127low
regulatory T cells and those who have less than 2.6% of
CD4+CD25hiCD127low regulatory T cells. Using Kaplan-Meier
analysis, patients who had higher levels of CD4+CD25hiCD127low
regulatory T cells were found to have better survival probability
compared to patients with lower CD4+CD25hiCD127low regula-
tory T cells, however this did not reach statistical significance
(p=0.075; Figure 5).
Discussion
The homeostasis between immune activation and immune
suppression is important in preventing tumorigenesis. The
immune system functions either to eliminate cancer cells or to
keep cancer cells in check by maintaining an equilibrium; if there
is a malfunction in the immune system, immune escape may
happen which then allows cancer cells to grow into clinically
Table 2. The correlation between TGF-b (A) and IL-10 (B) levels with patient clinico-pathological factors.
A
Factor N TGF-b p value
Mean ± SD
Staging 29
Early 10 882.506562.78
Late 19 822.936331.82 0.721
Ever chewer 30
Yes 18 818.886391.54
No 12 865.876453.55 0.765
Ever smoker 30
Yes 5 1339.586296.05
No 25 737.306354.90 0.001
Ever drinker 30
Yes 4 955.536385.28
No 26 819.556418.35 0.547
Mean Age 30
$58 22 795.836402.34
,58 8 953.766437.67 0.363
B
Factor N IL-10 p value
Mean ± SD
Staging 29
Early 10 4.1760.62
Late 19 4.5061.52 0.515
Ever chewer 30
Yes 18 4.4761.51
No 12 4.2360.79 0.626
Ever smoker 30
Yes 5 4.4861.21
No 25 4.3561.29 0.833
Ever drinker 30
Yes 4 4.0860.34
No 26 4.4161.35 0.630
Mean Age 30
$58 22 4.2160.88
,58 8 4.8161.98 0.255
doi:10.1371/journal.pone.0103975.t002
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apparent tumors [53]. The mechanisms by which tumor escapes
immune-surveillance include deregulation of the function of Tregs
and/or immune-regulatory cytokines.
In our study, the percentage of T lymphocytes in both the
OSCC patients and healthy donors were not significantly different.
Previous reports have demonstrated a reduction of T lymphocytes
in cancer patients, the main difference between our study and
these may lie in the fact that in our study, treatment naı¨ve patients
were recruited whereas most other studies included post-treated
cancer patients who had undergone chemo/radiotherapy which
could result in lymphodepletion [54,55]. Looking at the subsets of
T cells, a reduction in the CD8+ T cell population was observed,
which suggests a compromised immune system, as CD8+ T cells
are involved in adaptive immunity that is responsible for
eliminating tumor cells when the cancer develops [56]. This data
is consistent with a previous report where a reduction in the CD8+
T cell population was also observed in head and neck cancer
patients [57].
Tregs have been reported to be increased in the peripheral
blood of various cancers [7,13,58–60]. While the levels of
circulating Tregs have initially been reported to be increased in
head and neck cancers [60,61], emerging data showed no
differences in the Treg numbers between head and neck cancer
patients and healthy controls [43,62]. These discrepancies are
likely due to the differences in patient cohorts where a variety of
anatomical sub-sites were analyzed, and the utilization of different
markers in defining the Treg cell populations. While we observed a
significant increase in the Treg cell populations in OSCC patients
Table 3. The correlation between specific T cell populations and patient clinico-pathological factors.
A
Factor N CD4+CD25hiCD127low p value
Mean ± SD
Staging 33
Early 12 3.0861.41
Late 21 2.0160.80 0.027
Ever chewer 35
Yes 19 2.3761.16
No 16 2.7861.10 0.299
Ever smoker 35
Yes 6 2.7361.04
No 29 2.5261.17 0.678
Ever drinker 35
Yes 4 2.4560.97
No 31 2.5761.17 0.849
Mean Age 35
$58 22 2.5361.26
,58 13 2.5960.93 0.882
B
Factor N CD8+ T cells/regulatory T cells p value
Mean ± SD
Staging 27
Early 8 4.4262.89
Late 19 6.9067.36 0.369
Ever chewer 27
Yes 16 6.7364.52
No 11 5.3568.66 0.592
Ever smoker 27
Yes 6 7.42611.42
No 21 5.8164.50 0.748
Ever drinker 27
Yes 4 4.0661.71
No 23 6.5366.87 0.489
Mean Age 27
$58 19 6.7567.19
,58 8 4.7764.07 0.473
doi:10.1371/journal.pone.0103975.t003
Tregs in Oral Cancer Patients
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e103975
compared to healthy donors, Drennan et al. found no difference
despite using identical markers in identifying Tregs
(CD4+CD25highCD127low/2) [43]. The possible reason for this
discrepancy is that the current study analyzed OSCC patients
while Drennan and colleagues conducted their study purely on
patients with laryngeal and oropharyngeal cancers. Differences in
OSCC and oropharyngeal are well established, and the most
apparent is the involvement of HPV where up to 60% of
oropharyngeal cancer have been reported to be HPV positive
[63]. By contrast, the prevalence of HPV infection in OSCC is low
[64] and emerging data from our laboratory indicate that the
prevalence of HPV infection in Malaysia OSCC patients is in the
range of 1.5% (TG Kallarakkal et al; unpublished data), suggesting
that this could be one of the reasons for the discrepancy that is
observed. In our study, high levels of CD4+CD25hiCD127low cells
were found to be significantly increased in early stage OSCC
patients compared to late stage patients and further found to trend
with better patient survival. This seemingly contradictory obser-
vation of a better prognosis associated with higher levels of Tregs
could be explained by their role in reducing tumor-specific
immune-mediated inflammation which has been shown to drive
the progression of tumors in certain cases [65–67]. This finding is
in line with other studies demonstrating that the presence of Tregs
correlated with better loco-regional control in head and neck
cancer and the presence of Treg is an indicator of better overall
survival in Hodgkin’s lymphoma [12,68]. Indeed, adoptive
transfer of Tregs in mice has been shown to suppress colitis-
associated colon cancer and intestinal adenomas [69,70] and this
could likely be due to the ability of Tregs in reducing the effects of
chronic inflammation by down-regulating the expression of
cyclooxygenase-2 and pro-inflammatory cytokines including
TNF-a and IFN-c. This effect on other solid tumors remains to
be tested. Further, the CD8+ T cell/Treg ratio has been shown to
be significantly associated with patient survival [5,71], although a
meaningful reduction of this ratio in OSCC patients was observed,
correlation with patient survival was not significant. In addition a
subpopulation where CD127 is not expressed
(CD4+CD25hiCD127nil) was detected, this population has not
yet been reported and the significance and function if any, of this
cell population remains unclear.
In addition to the up-regulation of Tregs, the secretion of
immune regulatory cytokines particularly TGF-b and IL-10 is also
known to be a mechanism of immune suppression [72,73]. The
increase expression of IL-10 in head and neck squamous cell
carcinoma patients remains controversial. Several studies have
suggested that patients with advanced head and neck cancer have
elevated serum levels of IL-10 and this finding is associated with
poor prognosis [74,75]. However, others failed to detect a
differential expression of IL-10 in these patients [76,77]. The
main reason for these could be the inherent differences in tumours
from different sites of the head and neck where patients with oral
cavity cancers are more likely to have undetectable levels of IL-10
compared to other sub-sites [74]. In the present study, the IL-10
levels were decreased or undetectable in OSCC patients and were
not correlated with any patient’s demographic information. This is
consistent with the findings of Green et al. where IL-10 levels were
not associated with any clinicopathological parameters nor with
overall patient survival [78]. As for the serum levels of TGF-b,
both patients and healthy donors were found to have similar levels
of this cytokine. However, further analysis showed that smokers
had significantly higher levels of TGF-b compared with non-
smokers who incidentally were mainly betel quid chewers. TGF-b
is known to have complex and contradictory growth effects on
cancer cells [79] but the relationship between smoking and
increase in TGF-b levels is still not well understood and warrants
further investigation. Perhaps the lack of TGF-b and IL-10 is not
too surprising as others have demonstrated that in head and neck
cancers, Tregs that primarily secrete IL-10 and TGF-b are those
within the population of tumor infiltrating lymphocytes and are
not those in circulation [80].
In summary, the current findings are consistent with other
studies, OSCC patients have a compromised immune status where
the CD8+ T cell levels are reduced and the Treg population is
elevated. Within the OSCC patient cohort however, higher levels
of Treg were associated with better survival. A new group of T
cells that is CD4+CD25hiCD127nil have also been demonstrated
which has not been reported previously. The presence of this
population of cells particularly within the OSCC patients warrants
further investigation.
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